The SLAS International Conference and Exhibition is the flagship annual conference and exhibition presented by SLAS and the must-attend event dedicated to life sciences discovery and laboratory automation technology. Schedule...
Now in its 21st year, Advanced Therapies Week is the premier biotech partnering event in the United States. Bringing together leaders in research, therapeutic development, and advanced manufacturing. Join us...
IO360° Delivers 4 Key Benefits 1.Delivering a 360° IO Community to Network and Form Collaborations Build faster and more impactful collaborations with researchers, clinicians, biopharma leaders, investors and policymakers...
The road to first-in-human is one of the most pivotal—and complex—stages in drug development. It’s a journey that requires foresight, coordination, and a clear map connecting scientific innovation to operational...
The rapid growth of complex antibody modalities—including bispecifics, multispecifics, Fc-fusions, and emerging formats—has widened the gap between discovery-stage expression systems and manufacturability. Transient expression, still widely used for screening and...
Join Bioprocess Online Chief Editor Tyler Menichiello on February 11, at 11 a.m. Eastern, for an interactive panel discussion exploring how upstream and downstream development teams can work together to...
Join us at the Houston Life Sciences Commercial Real Estate Conference, where researchers, developers, investors, and real estate professionals converge to examine the forces shaping one of the fastest-growing innovation hubs...
In this Capabilities Update, industry leaders will share where AI is delivering value today—from hit-to-lead optimization and analytical method development to model-informed process development and digital CPV/QMS—and how CDMOs and...
2026 marks a turning point in life sciences — the year AI moves from concept to core capability. With ELaiN, the world’s first AI-native ELN, Sapio is leading this transformation, making software...
Ultrafiltration/Diafiltration (UF/DF) processes that look robust at the development scale often expose critical weaknesses during scale-up or tech transfer—resulting in capacity constraints, excessive manual intervention, delayed timelines, or manufacturing risk....
Join Us for the BVS and BioMed Realty Biotech Community Event! Mark your calendars for a great opportunity to connect with industry leaders, explore innovative products, and mingle with fellow...
Cell therapy development is entering a phase where complexity can no longer be managed by intuition alone. In this Cell & Gene Live, Cell & Gene’s Chief Editor, Erin Harris,...
